Anktiva (Nogapendekin Alfa Inbakic-PMln) Patent Expiration, LOE Window & CMS Spending

Anktiva (Nogapendekin Alfa Inbakic-PMln) by Altor , , An Indirect Wholly-Owned Su: Biologic BLA (Purple Book Regime), 0 AB generics, $2.9M 2024 CMS Part D & Medicaid spend, and $35,800 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAltor , , An Indirect Wholly-Owned Su
FDA Application & PathwayB761336 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.9M
2024 Medicare Part D Spend$2.9M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($35,800 intro WAC)